<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176849</url>
  </required_header>
  <id_info>
    <org_study_id>17-076</org_study_id>
    <nct_id>NCT03176849</nct_id>
  </id_info>
  <brief_title>A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT</brief_title>
  <official_title>A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phoenix Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research has suggested that children with sufficient vitamin D levels undergoing
      hematopoietic stem cell transplant (HSCT) have improved outcomes, including lower incidences
      of infection and graft-versus-host disease (GVHD), as well as overall improved survival.
      However, supplementation in children undergoing HSCT has shown to be a challenge using
      standard or aggressive supplementation strategies. The overall objective of our study is to
      determine the effectiveness of a single, high dose oral vitamin D at the start of transplant
      followed by maintenance supplementation in children undergoing HSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comorbidities and complications including infection, organ system toxicity, graft-versus-host
      disease (GVHD) and disease recurrence are some of the biggest contributors to quality of life
      and mortality in children undergoing hematopoietic stem cell transplant (HSCT). Research has
      suggested that patients with sufficient vitamin D levels during transplant have improved
      outcomes, including lower incidences of infection and acute GVHD, as well as overall improved
      survival. Prior research has shown that chronically ill children are at risk for vitamin D
      deficiency, including those undergoing HSCT. Data has shown populations with as many as 70%
      of HSCT patients have insufficient levels of vitamin D at time of transplant. While several
      studies have attempted methods of vitamin D supplementation in this subset of patients, there
      has not been success with either standard or aggressive supplementation strategies.

      Single high-dose oral vitamin D therapy, known as stoss therapy, has been used in other
      chronically ill children where adequate levels of vitamin D are difficult to attain. Stoss
      therapy suggests a single high-dose followed by maintenance dosing would be adequate to
      replete and maintain vitamin D levels in chronically ill children. While it has been shown to
      be effective with no evidence of toxicity in patients with rickets and cystic fibrosis, its
      safety and efficacy has not been studied in the transplant setting. However, there is an
      urgent need to identify a modifiable factor may reduce the occurrence and/or severity of HSCT
      associated complications. Our overall objective of this study is to determine the
      effectiveness of a single, high dose oral vitamin D followed by maintenance supplementation
      in children undergoing HSCT. This change will result in a new and innovative approach to
      maintaining adequate vitamin D levels during pediatric HSCT, with the long term goal of
      reducing morbidity and mortality.

      Our primary hypotheses are based on previous data referred to above. Our primary hypothesis
      is that a single, high dose of vitamin D followed by maintenance supplementation in children
      undergoing HSCT is a safe and efficacious way to replete vitamin D stores during HSCT through
      Day +100 of transplant. Our secondary hypothesis is that adequate vitamin D levels in
      patients undergoing HSCT have positive effect on the overall outcomes, including graft versus
      host disease, immune recovery, rejection, relapse, and infection rates.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients enrolled in the study will be randomized to either a control or intervention arm prior to the start of transplant using block randomization of blocks of 6. Those randomized to the intervention arm will receive the intervention (Stoss Therapy dosing of vitamin D) at the start of transplant followed by maintenance supplementation of vitamin D according to standard of care. Those randomized into the control arm will receive only maintenance supplementation of vitamin D according to standard of care throughout transplant.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Stoss Therapy</measure>
    <time_frame>100 days</time_frame>
    <description>In order to monitor the safety of stoss therapy, patients will be monitored for any clinical signs or symptoms of hypervitaminosis D, including abdominal pain, dehydration, and fatigue. Patients will be monitored for hypercalcemia and hyperphosphatemia with weekly complete metabolic panels and serum phosphorus during the first 100 days of transplant. Patients will have repeat measurements of serum 25(OH)D levels will be obtained at Day +30 to ensure they do not have hypervitaminosis D at that time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of vitamin D repletion</measure>
    <time_frame>100 days</time_frame>
    <description>All patients will have baseline serum 25(OH)D levels obtained prior to transplant. At baseline, patient will be classified as being sufficient (&gt;30ng/mL), insufficient (21- 29ng/mL), or deficient (&lt;20ng/mL) in serum vitamin D. All patients will then undergo treatment based on their trial arm and baseline levels of vitamin D. Patients will have repeat measurements of serum 25(OH)D levels will be obtained at Day +100 of transplant. At this time they will again be classified as being sufficient (&gt;30ng/mL), insufficient (21- 29ng/mL), or deficient (&lt;20ng/mL) in serum vitamin D following therapy to assess if the therapy was efficacious in repleting and maintaining their serum vitamin D level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease</measure>
    <time_frame>100 days</time_frame>
    <description>All incidences of GVHD will be recorded in the medical record throughout transplant as per standard of care for data extraction after Day +100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Recovery</measure>
    <time_frame>100 days</time_frame>
    <description>Immune recovery will be obtained at Day +100 as per standard of care and recorded in the medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rejection</measure>
    <time_frame>100 days</time_frame>
    <description>All incidences of rejection will be recorded in the medical record throughout transplant as per standard of care for data extraction after Day +100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>100 days</time_frame>
    <description>All incidences of relapse will be recorded in the medical record throughout transplant as per standard of care for data extraction after Day +100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection Rates</measure>
    <time_frame>100 days</time_frame>
    <description>All incidences of infection will be recorded in the medical record throughout transplant as per standard of care for data extraction after Day +100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>100 days</time_frame>
    <description>All incidences of mortality will be recorded in the medical record throughout transplant as per standard of care for data extraction after Day +100</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Pediatric Cancer</condition>
  <condition>Blood Disorder</condition>
  <condition>Pediatric Acute Myeloid Leukemia</condition>
  <condition>Pediatric Acute Lymphoid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Sickle Cell Anemia in Children</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Thalassemia in Children</condition>
  <arm_group>
    <arm_group_label>Single, high dose oral vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take a single oral dose of vitamin D3 based on age and initial vitamin D level. A patient may be sufficient, insufficient, or deficient at the start of therapy. Following this dose, patients will also be given standard vitamin D3 supplementation during transplant in accordance with current standard supplementation. This supplementation is also based on a patient's initial vitamin D level. If a patient had sufficient vitamin D at the beginning, but becomes deficient or insufficient at Day +30 of transplant, they will receive increased supplementation for the remainder of transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Vitamin D Supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be given standard vitamin D3 supplementation during transplant in accordance with current standard of care. This supplementation is based on a patient's initial vitamin D level. A patient may be sufficient, insufficient, or deficient at the start of transplant. If a patient had sufficient vitamin D at the beginning, but becomes deficient or insufficient at Day +30 of transplant, they will receive increased supplementation for the remainder of transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.</description>
    <arm_group_label>Single, high dose oral vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard Vitamin D3 Supplementation</intervention_name>
    <description>Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.
Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally.</description>
    <arm_group_label>Single, high dose oral vitamin D3</arm_group_label>
    <arm_group_label>Standard Vitamin D Supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All pediatric patients, ages 1 to 25 years of age, undergoing hematopoietic stem cell
             transplant at Phoenix Children's hospital

          -  Patients must sign an informed consent

        Exclusion Criteria:

          -  Prior rejection of hematopoietic stem cell transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Ngwube, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kayla Burgett</last_name>
    <role>Study Chair</role>
    <affiliation>Phoenix Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Ngwube, MD</last_name>
    <phone>602-933-0920</phone>
    <email>angwube@phoenixchildrens.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Bodea, MD</last_name>
    <phone>602-933-0920</phone>
    <email>jbodea@phoenixchildrens.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Ngwube, MD</last_name>
      <phone>602-933-0920</phone>
      <email>angwube@phoenixchildrens.com</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Bodea, MD</last_name>
      <phone>602-933-0920</phone>
      <email>jbodea@phoenixchildrens.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Ngwube, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Bodea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ccbd.phoenixchildrens.org/</url>
    <description>More information about Phoenix Children's Hospital's Center for Cancer and Blood Disorders</description>
  </link>
  <link>
    <url>http://ccbd.phoenixchildrens.org/research/clinical-trials</url>
    <description>More information about clinical trials at Phoenix Children's Hospital's Center for Cancer and Blood Disorders</description>
  </link>
  <reference>
    <citation>Duncan CN, Vrooman L, Apfelbaum EM, Whitley K, Bechard L, Lehmann LE. 25-hydroxy vitamin D deficiency following pediatric hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2011 May;17(5):749-53. doi: 10.1016/j.bbmt.2010.10.009. Epub 2010 Oct 15.</citation>
    <PMID>20951818</PMID>
  </reference>
  <reference>
    <citation>Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004 Jun;158(6):531-7.</citation>
    <PMID>15184215</PMID>
  </reference>
  <reference>
    <citation>Hansson ME, Norlin AC, Omazic B, Wikstr√∂m AC, Bergman P, Winiarski J, Remberger M, Sundin M. Vitamin d levels affect outcome in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct;20(10):1537-43. doi: 10.1016/j.bbmt.2014.05.030. Epub 2014 Jun 5.</citation>
    <PMID>24910378</PMID>
  </reference>
  <reference>
    <citation>Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr. 2008 Jun;87(6):1738-42.</citation>
    <PMID>18541563</PMID>
  </reference>
  <reference>
    <citation>Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6. Erratum in: J Clin Endocrinol Metab. 2011 Dec;96(12):3908.</citation>
    <PMID>21646368</PMID>
  </reference>
  <reference>
    <citation>Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008 Aug;122(2):398-417. doi: 10.1542/peds.2007-1894. Review.</citation>
    <PMID>18676559</PMID>
  </reference>
  <reference>
    <citation>Rosenblatt J, Bissonnette A, Ahmad R, Wu Z, Vasir B, Stevenson K, Zarwan C, Keefe W, Glotzbecker B, Mills H, Joyce R, Levine JD, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant. 2010 Sep;45(9):1463-8. doi: 10.1038/bmt.2009.366. Epub 2010 Jan 18.</citation>
    <PMID>20081878</PMID>
  </reference>
  <reference>
    <citation>Schlereth F, Badenhoop K. [Vitamin D : More than just a bone hormone]. Internist (Berl). 2016 Jul;57(7):646-55. doi: 10.1007/s00108-016-0082-2. Review. German.</citation>
    <PMID>27307163</PMID>
  </reference>
  <reference>
    <citation>Shepherd D, Belessis Y, Katz T, Morton J, Field P, Jaffe A. Single high-dose oral vitamin D3 (stoss) therapy--a solution to vitamin D deficiency in children with cystic fibrosis? J Cyst Fibros. 2013 Mar;12(2):177-82. doi: 10.1016/j.jcf.2012.08.007. Epub 2012 Sep 19.</citation>
    <PMID>22998937</PMID>
  </reference>
  <reference>
    <citation>Sullivan SS, Rosen CJ, Halteman WA, Chen TC, Holick MF. Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc. 2005 Jun;105(6):971-4.</citation>
    <PMID>15942551</PMID>
  </reference>
  <reference>
    <citation>Wallace G, Jodele S, Myers KC, Dandoy CE, El-Bietar J, Nelson A, Taggart CB, Daniels P, Lane A, Howell J, Teusink-Cross A, Davies SM. Vitamin D Deficiency in Pediatric Hematopoietic Stem Cell Transplantation Patients Despite Both Standard and Aggressive Supplementation. Biol Blood Marrow Transplant. 2016 Jul;22(7):1271-1274. doi: 10.1016/j.bbmt.2016.03.026. Epub 2016 Apr 1.</citation>
    <PMID>27044905</PMID>
  </reference>
  <reference>
    <citation>Wallace G, Jodele S, Howell J, Myers KC, Teusink A, Zhao X, Setchell K, Holtzapfel C, Lane A, Taggart C, Laskin BL, Davies SM. Vitamin D Deficiency and Survival in Children after Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2015 Sep;21(9):1627-31. doi: 10.1016/j.bbmt.2015.06.009. Epub 2015 Jun 18.</citation>
    <PMID>26093045</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Phoenix Children's Hospital</investigator_affiliation>
    <investigator_full_name>Jessie Bodea, MD</investigator_full_name>
    <investigator_title>Resident Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

